Cantor Fitzgerald Initiates Coverage on Rosetta Genomics, Veracyte | GenomeWeb

NEW YORK (GenomeWeb) – Cantor Fitzgerald yesterday initiated coverage of molecular diagnostic firms Rosetta Genomics and Veracyte with ratings of speculative buy and buy, respectively.

Cantor analyst Brian Brokmeier set a $3 to $5 fair value on Rosetta's shares, citing the firm's shift over the last year from a "niche player in the cancer of unknown primary (CUP) market into a molecular diagnostics lab with a portfolio of tests targeting the oncology market."

Rosetta's shares were trading up more than 11 percent at $1.38 during early morning trading on the Nasdaq Friday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.